BR0215115A - Tratamento de perda muscular com moduladores de receptores de androgênio seletivos - Google Patents

Tratamento de perda muscular com moduladores de receptores de androgênio seletivos

Info

Publication number
BR0215115A
BR0215115A BR0215115-4A BR0215115A BR0215115A BR 0215115 A BR0215115 A BR 0215115A BR 0215115 A BR0215115 A BR 0215115A BR 0215115 A BR0215115 A BR 0215115A
Authority
BR
Brazil
Prior art keywords
treatment
androgen receptor
receptor modulators
selective androgen
muscle loss
Prior art date
Application number
BR0215115-4A
Other languages
English (en)
Inventor
Mitchell S Steiner
Karen A Veverka
James T Dalton
Duane D Miller
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Publication of BR0215115A publication Critical patent/BR0215115A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"TRATAMENTO DE PERDA MUSCULAR COM MODULADORES DE RECEPTORES DE ANDROGêNIO SELETIVOS". A presente invenção apresenta:um método para o tratamento de um distúrbio de perda muscular; um método para a prevenção de um distúrbio de perda muscular em um indivíduo; um método para o tratamento, a prevenção, a supressão, a inibição ou a redução da perda muscular em um indivíduo que sofre de um distúrbio de perda muscular; um método para o tratamento, a prevenção, a inibição, a redução ou a supressão de perda muscular em um indivíduo que sofre de um distúrbio de perda muscular; e/ou um método para o tratamento, a prevenção, a inibição, a redução ou a supressão de catabolismo de proteína muscular em um indivíduo que sofre de um distúrbio de perda muscular, mediante a administração, ao indivíduo, de um modulador de receptor de androgênio seletivo (SARM) e/ou seu análogo, derivado, isómero, metabólito, sal farmaceuticamente aceitável, produto farmacêutico, hidrato, N-óxido ou qualquer combinação destes, tal como aqui descrito.
BR0215115-4A 2001-12-06 2002-12-05 Tratamento de perda muscular com moduladores de receptores de androgênio seletivos BR0215115A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33618501P 2001-12-06 2001-12-06
PCT/US2002/036147 WO2003049675A2 (en) 2001-12-06 2002-12-05 Treating muscle wasting with selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
BR0215115A true BR0215115A (pt) 2005-04-19

Family

ID=23314937

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215115-4A BR0215115A (pt) 2001-12-06 2002-12-05 Tratamento de perda muscular com moduladores de receptores de androgênio seletivos

Country Status (21)

Country Link
US (1) US7547728B2 (pt)
EP (2) EP1463497B1 (pt)
JP (2) JP4605557B2 (pt)
KR (1) KR100767317B1 (pt)
CN (1) CN1617715B (pt)
AT (1) ATE526959T1 (pt)
AU (1) AU2002364949C1 (pt)
BR (1) BR0215115A (pt)
CA (1) CA2469340A1 (pt)
CY (1) CY1112509T1 (pt)
DK (1) DK1463497T3 (pt)
EA (1) EA007921B1 (pt)
ES (1) ES2372929T3 (pt)
GE (1) GEP20063984B (pt)
HK (1) HK1068102A1 (pt)
HR (1) HRP20040588A2 (pt)
IL (2) IL162340A0 (pt)
MX (1) MXPA04005519A (pt)
PT (1) PT1463497E (pt)
TW (1) TWI339118B (pt)
WO (1) WO2003049675A2 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) * 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
ATE526959T1 (de) * 2001-12-06 2011-10-15 Gtx Inc Behandlung von muskelschwund mit selektiven androgenrezeptormodulatoren
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070066568A1 (en) * 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US7595402B2 (en) * 2003-12-16 2009-09-29 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US7776921B2 (en) 2002-02-07 2010-08-17 University Of Tennessee Research Foundation Treating benign prostate hyperplasia with SARMS
EP2266577B8 (en) * 2002-02-28 2015-01-21 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
ES2528764T3 (es) * 2002-02-28 2015-02-12 University Of Tennessee Research Foundation Moduladores selectivos multisustituidos del receptor de andrógeno y métodos de uso de los mismos
MXPA04009460A (es) * 2002-02-28 2006-04-27 Univ Tennessee Res Foundation Moduladores receptores de androgeno selectivo multi-sustituidos y metodos de uso de los mismos.
EP1543722B1 (en) * 2002-08-19 2015-04-15 Nagoya Industrial Science Research Institute Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy
CN1726034A (zh) * 2002-10-15 2006-01-25 田纳西大学研究基金会 亚甲基桥连的选择性雄激素受体调节剂及其应用方法
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
JP2006505564A (ja) * 2002-10-16 2006-02-16 ジーティーエックス・インコーポレイテッド Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
CN100462353C (zh) * 2003-06-27 2009-02-18 奥赖恩公司 用作雄激素受体调节剂的丙酰胺衍生物
MXPA05013619A (es) * 2003-06-27 2006-03-10 Orion Corp Nuevos compuestos.
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
CA2535953C (en) * 2003-10-14 2012-07-03 Gtx, Inc. Treating bone-related disorders with selective androgen receptor modulators
EP1737813A1 (en) * 2004-04-13 2007-01-03 Warner-Lambert Company LLC Androgen modulators
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
AU2005251781C1 (en) * 2004-06-07 2008-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
KR20070057792A (ko) 2004-07-16 2007-06-07 선에시스 파마슈티컬스 인코포레이티드 오로라 키나아제 저해물질로서 유용한 티에노피리미딘
US7655700B2 (en) * 2005-08-25 2010-02-02 Michigan State University Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles
AU2007272950B2 (en) * 2006-07-12 2012-11-01 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
MX2009001962A (es) 2006-08-24 2009-04-30 Univ Tennessee Res Foundation Acilanilidas substituidas y metodos de uso de las mismas.
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
NZ583624A (en) 2007-08-07 2012-06-29 Takeda Pharmaceutical Pyrrolidin-2-one derivatives as androgen receptor modulator
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CN103553966B (zh) * 2007-09-11 2016-09-07 Gtx公司 选择性雄激素受体调节剂的固体形态
CN101945853B (zh) 2007-12-21 2014-08-20 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
JP5808797B2 (ja) 2010-05-20 2015-11-10 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 筋萎縮を阻害するための方法
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
CA2838275C (en) 2011-06-06 2021-08-10 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
US20140371188A1 (en) * 2011-11-23 2014-12-18 University Of Iowa Research Foundation Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
EP2834216A1 (en) * 2012-04-04 2015-02-11 Catylix Inc. Selective androgen receptor modulators
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN104754939A (zh) 2012-07-13 2015-07-01 Gtx公司 用选择性雄激素受体调节剂(sarm)治疗雄激素受体(ar)阳性乳癌的方法
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP2015071549A (ja) * 2013-10-02 2015-04-16 株式会社ファンケル アトロジン−１抑制剤
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
KR20190077607A (ko) * 2014-10-16 2019-07-03 지티엑스, 인코포레이티드 Sarm을 이용하는 비뇨기 장애의 치료 방법
KR101919081B1 (ko) * 2017-05-11 2018-11-16 (주)녹십자웰빙 인간 태반 추출물을 유효성분으로 포함하는 근 위축증 또는 근육감소증의 예방 또는 치료용 및 근육 기능 개선용 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) * 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
US4336505A (en) * 1980-07-14 1982-06-22 John Fluke Mfg. Co., Inc. Controlled frequency signal source apparatus including a feedback path for the reduction of phase noise
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
DE3372965D1 (en) * 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US4633025A (en) 1985-04-15 1986-12-30 Miles Laboratories, Inc. Method for preparing (+)R-2-methyl-hexane-1,2-diol
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5847076A (en) * 1993-05-20 1998-12-08 Board Of Regents, The University Of Texas System Regulators of the proteasome
WO1995019770A1 (en) 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6995284B2 (en) * 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6569896B2 (en) * 2000-08-24 2003-05-27 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
AU7604798A (en) * 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
IL148192A0 (en) 1999-10-14 2002-09-12 Bristol Myers Squibb Co Crystals of androgen receptor ligand binding domain and methods utilizing the coordinates of the crystal structure
PL354620A1 (en) 1999-10-19 2004-02-09 Nobex Corporation Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
BR0015124A (pt) 1999-10-27 2002-07-02 Nobex Corp Método de preparação de um enanciÈmero substancialmente puro
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
KR20030016310A (ko) 2000-06-28 2003-02-26 브리스톨-마이어스스퀴브컴파니 선택적 안드로겐 수용체 조절제, 및 그의 확인, 고안 및사용 방법
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
IL154425A0 (en) * 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
ATE526959T1 (de) * 2001-12-06 2011-10-15 Gtx Inc Behandlung von muskelschwund mit selektiven androgenrezeptormodulatoren
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä

Also Published As

Publication number Publication date
PT1463497E (pt) 2011-12-20
US7547728B2 (en) 2009-06-16
EP1463497A4 (en) 2007-11-14
EP1463497B1 (en) 2011-10-05
ATE526959T1 (de) 2011-10-15
JP2010254707A (ja) 2010-11-11
US20040087557A1 (en) 2004-05-06
DK1463497T3 (da) 2012-01-30
KR100767317B1 (ko) 2007-10-17
CA2469340A1 (en) 2003-06-19
EP2289503B1 (en) 2016-06-29
JP2005516002A (ja) 2005-06-02
JP4605557B2 (ja) 2011-01-05
TW200410674A (en) 2004-07-01
CN1617715B (zh) 2010-05-12
MXPA04005519A (es) 2005-06-20
ES2372929T3 (es) 2012-01-27
CY1112509T1 (el) 2015-12-09
EP2289503A2 (en) 2011-03-02
EP1463497A2 (en) 2004-10-06
WO2003049675A2 (en) 2003-06-19
WO2003049675A3 (en) 2004-04-01
EA200400774A1 (ru) 2004-12-30
HRP20040588A2 (en) 2004-10-31
CN1617715A (zh) 2005-05-18
GEP20063984B (en) 2006-12-11
EA007921B1 (ru) 2007-02-27
HK1068102A1 (en) 2005-04-22
EP2289503A3 (en) 2011-04-06
KR20050044714A (ko) 2005-05-12
AU2002364949A1 (en) 2003-06-23
IL162340A (en) 2013-09-30
AU2002364949C1 (en) 2008-05-29
IL162340A0 (en) 2005-11-20
TWI339118B (en) 2011-03-21

Similar Documents

Publication Publication Date Title
BR0215115A (pt) Tratamento de perda muscular com moduladores de receptores de androgênio seletivos
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
MXPA03007140A (es) Derivados de carbolina.
IL161455A0 (en) Sterile, breathable patch for treating wound pain
HK1082203A1 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
CY1112817T1 (el) Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571
IL160754A0 (en) Dosage form, device and methods of treatment
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
EP1465968A4 (en) METHODS OF TREATING DISTILLATE DEODORIZER
EP1404871A4 (en) METHOD OF TREATING CANCERS ASSOCIATED WITH LEVELS OF HER-2 STUDENTS
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
HK1047239A1 (en) Concomitant drugs for treating glaucoma
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
MY122838A (en) Treating allergic and inflammatory conditions
EP1448193A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
DK1000046T3 (da) Piperazinderivater, der er aktive på den nedre urinvejskanal
PL349309A1 (en) Creatine fibre protecting composition, method of protecting creatine fibre and treatment set for chemically treating creatine fibre
EP1419236A4 (en) METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
EP1458694A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
WO2003059332A3 (en) Use of an anti-microtubule agent for the treatment of uveitis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL